Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study

Exclusion Criteria

• •1. Subjects who are unable or unwilling to sign the informed consent form.
• •2. Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.
• •3. Subjects with serious co-morbid conditions that in judgment of the investigator preclude inclusion in this study
• •4. Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction \< 30%.
• •5. Subjects with an ST elevation myocardial infarction.
• •6. Subjects with hemodynamic or electrical instability (including shock).
• •7. Subjects diagnosed with severe, non-catheter-related coronary artery spasm.
• •8. Subjects who are or may be pregnant.
• •9. Subjects with known allergies to contrast media.
• •10. Subjects with eGFR \< 60 ml/min/1.73m2.
• •11. Subjects currently taking oral anticoagulants with an absolute contraindication to discontinuation of anticoagulation.
• •12. History of TIA or stroke \< 6 months.
• •13. History of hemorrhagic stroke.
• •14. Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia.
• •15. Cardiac catheterization scheduled within 4 hours of randomization or more then 72 hours after randomization.
• •1. Lesions located in the left main coronary artery
• •2. Lesions that are heavily calcified
• •3. Lesions where OCT cannot be performed due to technical difficulties
• •4. Other lesions that the investigator deems inappropriate for the procedure such as sites with excessive tortuosity or low flow by TIMI grade.
• •5. Lesions in saphenous vein grafts or arterial conduits.